Organization: Health Canada
Year: 2023
Month: June
Request Number: A-2023-000024
Request Summary: The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal ingredient Levothyroxine sodium. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for Levothyroxine sodium which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24. The strength (s) and dosage form of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal ingredient Levothyroxine sodium.
Disposition: Disclosed in part
Number of pages: 4